SCHEMBL10109262

SCHEMBL10109262

COc1ccc([C@@H]2Cc3c(C#N)cc(OC)cc3[C@@H]3CCCC[C@H]23)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
GAA P10253 3/20 0.37
BLM P54132 1/20 0.37
KDM1A O60341 2/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
MAPT P10636 3/20 0.35
HSD17B10 Q99714 2/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
AR P10275 4/20 0.34
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL317922 1.00 MEN1 (0.37) MEN1KMT2AGAABLMKDM1A
SCHEMBL10109225 0.83 ESR1 (0.38) KMT2AKDM1AMAOAMAOBALDH1A1
SCHEMBL318409 0.83 ESR1 (0.38) KMT2AKDM1AMAOAMAOBALDH1A1
SCHEMBL10108896 0.81 CYP3A4 (0.43) MEN1KMT2AKDM1AMAOAMAOB
SCHEMBL318064 0.81 CYP3A4 (0.43) MEN1KMT2AKDM1AMAOAMAOB
SCHEMBL319089 0.81 ESR1 (0.40) KMT2AKDM1AMAOAMAOBALDH1A1
SCHEMBL10109158 0.81 ESR1 (0.40) KMT2AKDM1AMAOAMAOBALDH1A1
SCHEMBL318639 0.80 ESR1 (0.38) KDM1AMAOAMAOBMAPTALDH1A1
SCHEMBL10109244 0.80 ESR1 (0.38) KDM1AMAOAMAOBMAPTALDH1A1
SCHEMBL10109246 0.79 SMN1; SMN2 (0.39) MEN1KMT2AGAAKDM1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093302-B2 Substituted tetralins as selective estrogen receptor-β agonists ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ESR2, ERLIN1, ESRRG MEN1 2698/4885KMT2A 2706/4885GAA 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.